pp-231 Solution for injection
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Geographic Atrophy (retinal disease) / Clinical stage: Phase 2 / Modality: Biologic - novel complement inhibitor / Mechanism & Target: Next-generation complement pathway inhibitor / Route & form: SC or IV / Differentiation: Combination therapy approach; comprehensive complement blockade
Manufacturer #39438
| Clinical-stage biopharmaceutical company developing targeted complement pathway inhibitors. Advances next-generation C3 inhibitors for ophthalmological and inflammatory disease indications. Expands pipeline through innovative molecular design across multiple therapeutic areas. |
None